The development of resistance to therapy remains the main barrier to cure myeloma, and most patients develop disease that is refractory to treatments, including proteasome inhibitors (PIs), immunomodulatory drugs (IMiDs) and monoclonal antibodies targeting CD38. The gene discussed is CD38; the disease is plasma cell myeloma.